Search results - Portal of Medical Data Models (MDM-Portal)

Filter search results

Reset filter

Keywords

Hematology ×

Baseline ×

Show more Keywords

Select data models

Selected data models

You must log in to select data models for download or further analysis.

3 Search results.

Baseline Local Laboratory Data, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - Baseline Local Laboratory Data, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

- 4/1/22 - 1 form, 3 itemgroups, 18 items, 1 language

Itemgroups: Hematology,Biochemistry,Pregnancy Tests

Sponsor: OSI Pharmaceuticals Information provided by : Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Baseline Local Laboratory Data

Open-label Baseline Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - Open-label Baseline Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

- 9/27/16 - 1 form, 8 itemgroups, 27 items, 1 language

Itemgroups: Vital Assessment,Physical Examination,Pregnancy Test,Hematology,Biochemistry/Proteomics,Cigarette Smoking Status,Tobacco/Nicotine Use Status,Open-label Tarceva Dispensed

Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Open-label Baseline Assessments

Baseline Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - Baseline Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

- 9/27/16 - 1 form, 16 itemgroups, 104 items, 1 language

Itemgroups: Medical and Surgical History,Significant Medical and Surgical History,NSCLC Diagnosis,NSCLC-related Surgery,Tobacco/Nicotine History at Randomization,Prior Adjuvant Chemotherapy,Prior Adjuvant Chemotherapy for NSCLC,Optional Research Blood Sample,Radiology,Vital Assessment,Physical Examination,Pregnancy Test,Hematology,Biochemistry/Proteomics,Study Drug Dispensed,Investigator's Signature

Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc ( OSI Pharmaceuticals ) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of Study: Baseline Assessments

Keywords

Table of contents

Selected data models

3 Search results.

Baseline Local Laboratory Data, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - Baseline Local Laboratory Data, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

Open-label Baseline Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - Open-label Baseline Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

Baseline Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - Baseline Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

Contact

Help